A panel of four cytokines predicts the prognosis of patients with malignant gliomas

Journal of Neuro-Oncology

Volumn 114, Issue 2, 2013, Pages 199-208

  Lin, Yi ^a   Zhang, Guozhen ^b   Zhang, Jing ^c   Gao, Guangzu ^d   Li, Min ^e   Chen, Yong ^f   Wang, Jiangfei ^b   Li, Guilin ^b   Song, Sonya Wei ^g   Qiu, Xiaoguang ^b   Wang, Yunjie ^a   Jiang, Tao ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^g PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Cytokine; Glioma; Overall survival; Plasma; Prognostic markers

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCOPROTEIN GP 130; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1DELTA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN IL1R4; SOLUBLE GP130 PROTEIN; SOMATOMEDIN BINDING PROTEIN 6; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE;

ADULT; ARTICLE; ASTROCYTOMA; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; BLOOD; BRAIN NEOPLASMS; CANCER GRADING; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOMA; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; ASTROCYTOMA; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROGNOSIS; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84885061104     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1171-x     Document Type: Article

References (41)

1. Louis D, Ohgaki H, Wiestler O, Cavenee W (2007) WHO classification of tumours of the central nervous system. IARC, Lyon
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
3. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12:116-121
4. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360-369. doi: 10.1111/j.1750-3639.2008.00129.x
5. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560-1566
6. Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, Qiu X, Jiang T, Zhang W, Song SW (2009) Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol 11:468-476
7. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12:5698-5704. doi: 10.1158/1078-0432.CCR-06-0181
8. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M (2007) Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130:3336-3341
9. Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, Takiguchi M, Tanzawa H, Yamaura A, Seki N (2005) Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 65:5190-5194
10. Quan N, Herkenham M (2002) Connecting cytokines and brain: a review of current issues. Histol Histopathol 17:273-288
11. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13:1359-1362
12. Muller L, Pawelec G (2003) Cytokines and antitumor immunity. Technol Cancer Res Treat 2:183-194
13. Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, Bigbee WL, Lokshin AE (2005) Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark 1:259-269
14. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE (2005) Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:981-987
15. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25:94-102
16. Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, Michalski W, Chechlinska M (2005) Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I - an independent prognostic factor. Tumour Biol 26:186-194
17. Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, Winans M, Bigbee W, Siegfried J, Lokshin A, Ferris RL (2007) Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 16:102-107
18. Katsumata N, Eguchi K, Fukuda M, Yamamoto N, Ohe Y, Oshita F, Tamura T, Shinkai T, Saijo N (1996) Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 2:553-559
19. Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, Alberg AJ, Harris CC (2009) Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 18:215-222
20. Jiang Y, Valente AJ, Williamson MJ, Zhang L, Graves DT (1990) Post-translational modification of a monocyte-specific chemoattractant synthesized by glioma, osteosarcoma, and vascular smooth muscle cells. J Biol Chem 265:18318-18321
21. Kasahara T, Mukaida N, Yamashita K, Yagisawa H, Akahoshi T, Matsushima K (1991) IL-1 and TNF-alpha induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line. Immunology 74:60-67
22. Nitta T, Sato K, Allegretta M, Brocke S, Lim M, Mitchell DJ, Steinman L (1992) Expression of granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor genes in human astrocytoma cell lines and in glioma specimens. Brain Res 571:19-25
23. Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, Ushio Y (1993) Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst 85:1836-1839
24. Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A, Voulgari P, Polyzoidis K, Kyritsis AP (2010) Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol 226:136-142
25. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
26. Lynch DH, Namen AE, Miller RE (1991) In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur J Immunol 21:2977-2985
27. Sica D, Rayman P, Stanley J, Edinger M, Tubbs RR, Klein E, Bukowski R, Finke JH (1993) Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma. Int J Cancer 53:941-947
28. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T (1993) Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82:1120-1126
29. Weiergraber O, Hemmann U, Kuster A, Muller-Newen G, Schneider J, Rose-John S, Kurschat P, Brakenhoff JP, Hart MH, Stabel S et al (1995) Soluble human interleukin-6 receptor. Expression in insect cells, purification and characterization. Eur J Biochem 234:661-669
30. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J (2011) The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 90:484-494
31. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J (2008) Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111:1021-1028
32. Kropf P, Herath S, Klemenz R, Muller I (2003) Signaling through the T1/ST2 molecule is not necessary for Th2 differentiation but is important for the regulation of type 1 responses in nonhealing Leishmania major infection. Infect Immun 71:1961-1971
33. Amatucci A, Novobrantseva T, Gilbride K, Brickelmaier M, Hochman P, Ibraghimov A (2007) Recombinant ST2 boosts hepatic Th2 response in vivo. J Leukoc Biol 82:124-132
34. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479-490
35. Takezako N, Hayakawa M, Hayakawa H, Aoki S, Yanagisawa K, Endo H, Tominaga S (2006) ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. Biochem Biophys Res Commun 341:425-432
36. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WO (2010) A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 363:1211-1221
37. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M (2002) History of allergies among adults with glioma and controls. Int J Cancer 98:609-615
38. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ (1989) Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 169:1449-1459
39. Takeshima H, Kuratsu J, Takeya M, Yoshimura T, Ushio Y (1994) Expression and localization of messenger RNA and protein for monocyte chemoattractant protein-1 in human malignant glioma. J Neurosurg 80:1056-1062
40. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34-40
41. Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S, Weller M (2003) Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 54:388-392